Improvement of relapse or infection incidence in patients with refractory leukemia receiving allogeneic hematopoietic stem cell transplantation

2015 Fiscal Year Final Research Report

• Project/Area Number: 24701031
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Clinical oncology
• Research Institution: Osaka City University
• Principal Investigator: KOH HIDEO 大阪市立大学, 大学院医学研究科, 講師 (90419698)
• Research Collaborator: NAKAMAE Hirohisa 大阪市立大学, 大学院医学研究科, 准教授 (30364003)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: 分子疫学 / 同種造血幹細胞移植 / 腫瘍再発抑制

Outline of Final Research Achievements

We examined the impact of killer immunoglobulin-like receptor (KIR) genotype/haplotype and single nucleotide polymorphisms (SNPs) of NKG2D, Toll-like receptor (TLR) 4, TLR9, CTLA-4 and HMGB-1 on relapse-free survival (RFS) of 121 patients with refractory hematological disorders who received related-donor hematopoietic cell transplantation (HCT). In analysis of the patients receiving HLA haploidentical peripheral blood stem cell transplantation using posttransplantation cyclophosphamide, KIR haplotype AA recipients from KIR Bx donors showed marginally significantly higher RFS than those from KIR AA donors (48% vs 9%, Log-rank P=0.088). There seemed to be no significant associations between RFS and KIR haplotype or the above-mentioned SNPs in the patients receiving HLA matched/mismatched related-donor HCT.

Free Research Field

臨床腫瘍学、血液学